The HLA class I-restricted cytotoxic T lymphocyte (CTL) response is a major defense mechanism in viral infections. It has been suggested that the CTL response may contribute to viral clearance and liver cell injury during hepatitis C virus (HCV) infection. To test this hypothesis requires an understanding of the characteristics of HCV-specific cytotoxic effector cells and identification of the target antigens to which they respond. To begin this process we stimulated peripheral blood mononuclear cells (PBMC) from a group of HLA-A2 positive patients with chronic hepatitis C with a panel of 130 HCV-derived peptides containing the HLA-A2 binding motif. Effector cells were tested for their capacity to lyse HLA-A2-matched target cells that were either sensitized with peptide or infected with a vaccinia virus construct containing HCV sequences. Using this approach we have identified nine immunogenic peptides in HCV, three of which are derived from the putative core protein, three from the nonstructural (NS) 3 domain, two from NS4 and one from NS5. Selected responses were shown to be HLA-A2 restricted, mediated by CD8+ T cells and to recognize endogenously synthesized viral antigen. Unexpectedly, peptide-specific CTL responses could also be induced in sero-negative individuals, suggesting in vitro activation of naive CTL precursors. The precursor frequency of peptide-specific CTL was 10 to 100-fold higher in infected patients compared to uninfected controls, and Definition of the molecular targets of the human CTL response to HCV creates this opportunity, and may also contribute to the development of a T cell-based HCV vaccine.
Introduction
The hepatitis C virus (HCV)' is the major cause of non-A, non-B viral hepatitis (1, 2, 3) . The most striking feature of HCV induced liver disease is its tendency towards chronicity and slowly progressive liver cell injury. The mechanisms responsible for tissue injury in acute and chronic HCV infection are not well understood and it is possible that both direct, virus related, or indirect, i.e., immunologically mediated, mechanisms may be involved.
While the CD4+ T cell response certainly plays a role in viral resistance and immunopathology, its involvement at the effector cell level is unclear since it is targeted primarily at internalized extracellular antigens in the context of HLA class II molecules, and because multiple, often antagonistic, functions have been attributed to the different subsets of CD4 + T helper cells (4) . HLA class I-restricted cytotoxic T lymphocytes (CTL), on the other hand, are widely acknowledged as a major effector mechanism in viral infections. CTL-mediated lysis of virus infected cells is thought to lead to clearance of the virus or, if incomplete, to viral persistence and chronic tissue injury (5) . Virus-specific CTL have been demonstrated in the peripheral blood (6, 7, 8) and in the liver (9) during acute viral hepatitis caused by the hepatitis B virus (HBV). Based on these observations, and on parallels with other viral diseases, immunologically mediated liver cell injury is thought to be responsible for chronic hepatitis after infection with HCV (10) . The recent demonstration of HCV-specific CTL in the intrahepatic inflammatory infiltrates of patients with chronic hepatitis C provide further support for this concept (11) .
CD8 + CTL interact through their polymorphic T cell receptors with HLA class I molecules containing endogenously synthesized peptides of 8 to 11 residues (usually 9 or 10) on the surface of infected cells (12) . The peptide binding motifs of many common HLA class I alleles such as A2.1, Aw68, B7, B27, and HLA-C have been published (13) (14) (15) (16) (17) . Because of the high frequency of the HLA A2. 1 allele in most populations (Caucasians: 46%; Japanese: 43%; Chinese: 55%; Africans: 27%), we have used HBV derived synthetic peptides containing the HLA-A2.1 binding motif to identify and characterize the HLA-A2-restricted CTL response in the peripheral blood during acute HBV infection (6-8, 18, 19) . We now report the successful use of this approach for the detection of HCV-specific CTL in the peripheral blood of patients with chronic HCV infection, and also (in lower numbers) in seronegative controls.
Methods
Patient population. All patients and normal subjects included in this study were HLA-A2 positive. The diagnosis of HCV infection was 
HLA ALT ndl * The diagnosis of HCV infection was based on standard serological assays using the second-generation (c200/c22-3) Ortho HCV ELISA test system (Ortho Diagnostics, Inc., Raritan, NJ). HCV RNA was detected using a nested cDNA polymerase chain reaction assay with primers selected from the 5' noncoding region and subsequent hybridization using an internal probe. * CAH = biopsy proven chronic active hepatitis (CAH) with or without cirrhosis (C) . t This subject was convalescent from hepatitis B infection (HBsAg negative, anti-HBs positive, antiHBc positive, anti-HBe positive). 11 This subject had no history of hepatitis and had normal liver enzymes, no biopsy was performed. I This subject had an episode of acute hepatitis C three months previously, no biopsy was performed.
based on standard clinical parameters and serological assays using the second-generation (c200/c22-3) Ortho HCV ELISA test system (Ortho Diagnostics, Inc., Raritan, NJ). 10 patients had biopsy proven chronic hepatitis (C-l to C-10) and two patients had anti-HCV antibodies without signs of liver disease (H-1 and H-2). One of these patients (C-3) also had a clinical history and serological evidence of acute HBV infection 3 mo before his entry into this study. The pertinent serological and clinical parameters defining this group of patients are listed in Table I (22) ) that contain the classical HLA-A2 binding motif (i.e., a leucine in the second position and a valine at the carboxy terminus) were selected for our initial studies. This panel contained two peptides from the core region, two from El, 6 from E2/NS1, 9 from NS2, nine from NS3, 10 from NS4, and 15 from NS5. An additional 77 peptides (panel 2) that contain an extended HLA-A2 motif (leucine, methionine, isoleucine or valine in the second position and valine, leucine or isoleucine at the carboxy-terminus) and are conserved in 100% of the HCV-la genotype (22) sequences in the GenBank database was subsequently studied. This panel contained 9 peptides from the core region, 4 from El, 9 from E2/NS1, 18 from NS3, 12 from NS4, and 24 from NS5. Two peptides previously identified as CTL epitopes in patients with acute hepatitis B, HBV core 18-27 (FLPSDFFPSV) (6) and HBVenv335-343 (WLSLLVPFV) (8) , were used as controls. All peptides were produced by Chiron Mimotopes (Clayton, Australia) and contained free amine N-termini and free acid C-termini. Lyophilized peptides were reconstituted at 20 mg/ml in DMSO (Malinckrodt, Paris, KY) and diluted to 1 mg/ml with RPMI 1640 medium (GIBCO BRL, Grand Island, NY).
PCR analyses ofpatient samples. HCV RNA was detected in sera using a nested cDNA polymerase chain reaction assay with primers selected from the 5' untranslated region and subsequent hybridization using an internal probe as previously described (23) . All seronegative controls (N-l through N-6) as well as patients with chronic hepatitis B infection (B-l through B4) had no detectable HCV RNA in the serum.
Stimulation of PBMC with synthetic peptides and tetanus toxoid. PBMC from donors were separated on Ficoll-Hypaque density gradients (Sigma Chemical Co., St. Louis, MO), washed three times in Hanks balanced salt solution (HBSS) (GIBCO BRL) resuspended in RPMI 1640 medium (GIBCO BRL) supplemented with L-glutamine (2 mM), gentamicin (10 tzg/ml), penicillin (50 U/ml), streptomycin (50 jig/ ml), and Hepes (5 mM) containing 10% heat-inactivated human AB serum (complete medium) and plated in 24-well plates at 4 x 106 cells/well. PBMC from patients C-1 through C-7, H-1 and H-2 were stimulated individually with the synthetic peptides from panel 1 at a final concentration of 10 ,g/ml. PBMC from patients C-8 and C-9 were stimulated with pools of peptides from panel 2 containing four peptides per pool at a final concentration of 2.5 ,Ag/ml per peptide. PBMC from patients C-3, C-7, C-10, Bl4, and NI4 were stimulated with selected individual HCV and HBV peptides as described above. In all cases, tetanus toxoid (Connaught Laboratories, Swiftwater, PA) was added at 1 ,ug/ml during the first week of stimulation. On day 3, 1 ml of complete medium supplemented with rIL2 (Hoffman-La Roche, Nutley, NJ) at 10 U/ml final concentration was added in each well. On day 7, the cultures were restimulated with the original peptide (or peptide pool) plus rIL2 and irradiated (3,000 rads) autologous feeder cells, and the cultured PBMC were tested for CTL activity against the stimulating peptide (or pool) on day 14 . Selected cultures that displayed peptidespecific cytolytic activity after 2 wk of stimulation were expanded by weekly restimulation with 1 X 106 irradiated (3,000 rads) autologous PBMC in 1 ml of complete medium containing 10 ,g/ml peptide and 20 U/ml IL2, and tested against the stimulating peptide, or constituent peptides (in the case of peptide pools) and against target cells infected with recombinant HCV-vaccinia viruses (see below).
Cell separation. CD4-and CD8-positive T cells were purified by panning using po sitive selection with anti-CD4 or anti-CD8 antibodies and depletion of CD45 RO positive cells was done using negative selec- 4-h 51Cr-release assay using U-bottom 96-well plates containing 5,000 targets per well. All assays were performed in duplicate. Percent cytotoxicity was determined from the formula: 100 x [(experimental release -spontaneous release)/(maximum release -spontaneous release)]. Maximum release was determined by lysis of targets with detergent (1% Triton X-100; Sigma Chemical Co.). Spontaneous release was < 25% of maximal release in all assays. A difference in the specific lysis of peptide pulsed target cells and nonpulsed target cells of 15% at an effector to target cells ratio between 40 and 80:1 in the initial CTL assay performed after 2 wk of culture was arbitrarily considered to represent a positive CTL response, and was confirmed by retesting after additional rounds of restimulation and subsequent cloning. The peptide-specific cytotoxicity observed against the HCV derived peptides that were not found to be CTL epitopes was typically below 5% (range 0-12%).
Limiting dilution analysis. Three or four different responder cell concentrations were set up in 24 replica cultures in complete medium and peptide (10 Ag/ml) complemented with graded numbers of autologous irradiated PBMC (3,000 rads) to give a total cell number of 1 x 106 (1 ml cultures in 48-well plates) or 0.2 x 106 (0.2 ml cultures in 96-well plates). A fixed number of 0.1 X 106 autologous irradiated PBMC was used for the CD45RO-depletion experiments (0.2 ml cultures in 96-well plates) to prevent the introduction of an experimental bias due to removal of CD45 RO+ antigen presenting cells. On days 3 and 10 rIL2 at 10 U/ml final concentration was added in each well. On day 7 and 14, the cultures were restimulated with the original peptide plus rIL2 and irradiated (3,000 rads) autologous feeder cells (1 X 106/ ml) and on day 21 the individual cultures were split and tested for CTL activity against JY target cells sensitized with the stimulating peptide or with medium alone. The cutoff point to define a positive response was calculated as the mean±2SD of peptide-specific killing of negative wells. The test was initially developed for the quantitation of influenza virus matrix peptide M58-68 (27) (Cerny et al. manuscript in preparation). The CTL precursor frequencies estimates and confidence intervals were calculated using the ELIDA software by Carl Taswell (28) . HLA typing. HLA typing of PBMC from patients and from normal donors was determined by microcytotoxicity, using HLA typing trays (One Lambda, Canoga Park, CA). The HLA haplotypes of patients participating in this study are shown in Table I .
Results
Screening of HCV peptide-specific responses. In this experiment ( Fig. 1 ) PBMC from eight HLA-A2 positive HCV infected subjects were stimulated individually with the 53 peptides from HCV panel 1, and cultures were tested after 2 wk of initial expansion for peptide-specific CTL activity. Peptidespecific cytotoxic T cell activity was observed against seven of the peptides (Table II) . Three of the subjects studied (3/6 with CAH) responded to at least one of the peptides. Subject C-2 responded to five peptides, two of which are derived from HCV core, one from NS3, NS4 and NS5 respectively. Subject C-3 60 C-1 responded to three peptides, including HCV core 178-187 but not HCV core 131-140. Several of the peptides, especially NS3 1406-1415 were found to be stimulatory for more than one patient, possibly reflecting a higher degree of immunogenicity. It is notable that 46 of the 53 peptides were nonstimulatory to these patients and that five of the patients (C-1, C-4, C-6, H-1, H-2) did not respond to any of the peptides in the panel. Restimulation of cultures yielding a marginal CTL response at 2 wk revealed additional responses in subject C-5 to HCV core 131-140, C-3 to NS3 1169-1177 and H-1 to NS4 1789-1797.
To determine whether the in vitro expansion of CTL using synthetic peptides reflects previous in vivo exposure, we analyzed the responses of four HCV infected patients (C-3, C-7, C-10, H-2), four patients with chronic HBV infection (B-1 to B-4), and four normal seronegative control subjects (N-I to N-4) using four of the foregoing stimulatory HCV peptides and two known HBV epitopes (Fig. 2, Experiment I) . Interestingly, we observed CTL responses to the HCV peptides in several HCV-uninfected subjects after 2 wks of stimulation, while a CTL response to the HBV peptides was seen only in patient C-3, who was recently convalescent from acute HBV infection, and patients B-2 and B-3, who were chronically infected by HBV. This was confirmed by another smaller experiment (Fig.  2 , Experiment II) using 2 HCV and one HBV-peptide for the stimulation of PBMC derived from two patients with chronic hepatitis C (C-3, C-7), two with chronic hepatitis B (B-3, B-4), and two normal healthy controls (N-2, N4). The observed Table H. Characterization of HCV peptide-specific CTL lines and clones. To establish highly cytotoxic T cell lines for further study and generation of CTL clones, we restimulated the responsive cultures weekly with autologous irradiated PBMC, peptide and IL-2. Fig. 3 shows an example of typical CTL lines, obtained from patient C-3 after four weeks of peptide stimulation, that are specific for HCV core 178-187, NS3 1169-1177 and NS3 1406-1415, and lyse HLA A2-matched peptide-pulsed EBV-BCL in a dose-dependent fashion. For most of these lines we generally observed a progressive increase of cytolytic activity after each round of peptide stimulation (Table III) . Interestingly, for the CTL response of subject C-2 to NS5 2252-2260 we observed 29% specific cytotoxic activity at an E/T of 84/ 1 after 2 wk of stimulation in one blood sample, although we could not detect any significant CTL activity after 2 or 3 wk of stimulation of PBMC collected two months later. Continuing restimulation of PBMC from the later date revealed peptidespecific CTL after 4 and 5 wk, however. While this may reflect fluctuation of the CTL precursor frequency in the course of HCV infection, it could also reflect the in vitro induction of peptide-specific CTL. This was addressed in an additional experiment (Table HI, Experiment C) comparing NS3 1406-1415 stimulated cultures derived from HCV infected subject C-7 and uninfected donor N-2. Whereas CTL were readily detectable in patient C-7 after 2 wk of stimulation, 4 wk of repetitive stimulation were required before peptide-specific CTL became detectable in subject N-2. As shown below, these differences correlate with a lower peptide-specific CTL precursor frequency in C-7 as compared to N-2 ( Fig. 6 B) HLA restriction analysis. HLA class I restriction analysis of the CTL response to two epitopes was performed as shown in Fig. 4 and Table IV. This analysis was done using allogeneic EBV-BCL that are partially matched with the effector cells at class I. As shown in Fig. 4 , the presence of the HLA-A2 allele is both required and sufficient for recognition and lysis of target cells by the CTL line specific for HCV core 178-187 derived from patient C-3. Similar results are shown for the response for the HCV NS3 1406-1415 specific CTL response of subject C-2 (Table IV, A) . Since all of the peptides used in this study contained the HLA-A2.1 binding motif, rigorous HLA-restriction analysis such as this was not performed in all patients. Since the EBV-BCL target cell most frequently used in our study (JY) is HLA-A2, B7, and Cw7 positive, it is theoretically possible, that some of the CTL responses could be B7 or Cw7 restricted. We think that this is unlikely especially since the binding motif for B7 and Cw7 have been elucidated recently and they differ considerably from the A2.1 motif (16, 17) .
Recognition of peptide-sensitized target cells: dose-response and specificity analysis. Increasing concentrations of HCV core 178-187 peptide were used to sensitize target cells for lysis by a peptide-specific CTL line derived from patient C-2. As illustrated in Table IV (B), optimal target cell sensitization occurred at a concentration of 1 MLM. Importantly, the cell line did not recognize target cells sensitized with another HLA-A2 binding peptide, HBVcore 18-27 (Table IV, C), confirming the specificity of the response for the inducing peptide.
Cell surface phenotype. Positively selected CD4 + and CD8 + cells from an HCV core 178-187 specific CTL line from patient C-2 were tested for peptide-specific recognition and lysis of an HLA-A2 matched EBV-BCL. Cytotoxic activity was limited to the CD8+ subpopulation (Table IV, D) . The analysis was further extended to the clonal level and cytotoxic T cell clones were derived from lines by cloning using limiting dilution. The Effector/Target Cell Ratio * PBMC derived from subject C-2 were stimulated with HCV-derived synthetic peptides and restimulated weekly with autologous antigen presenting cells and peptide as described. $ EBV-BCL were used as target cells matching effector cell class I allele expression as indicated. Target cell sensitization was performed overnight using the peptides at the concentrations shown. I Peptide specific cytotoxic activity using 25 effector cells per target cell obtained in a 4-h 5"Cr-release assay. 11 CD4+ and CD8+ cell populations were purified as described yielding 79% CD4+ cells and 87% CD8+ cells respectively in the experiment shown. ysis, respectively). The experiment in Fig. 6 C demonstrates that subject C-8 displayed at least 10-fold higher CTL precursor frequency to HCV core 131-140 than normal donor N4 displayed to the HBV core 18-27 epitope. The low precursor frequency to the HBV epitope is in the same barely detectable range as the CTL precursor frequency to HCV NS3 1406-1415 in uninfected normal donors shown in the previous two experiments. Finally, as illustrated in D, the CTL precursor frequency to HBV core 18-27 was shown to be 1/106 PBMC in chronic hepatitis B patient B-3 who responded to this peptide with 46% specific killing in bulk culture (Fig. 2, Experiment  I) . In contrast, the CTL precursor frequency to this peptide was at least 25-fold lower in normal donor N-6 who did not respond in bulk culture in the same experiments (Fig. 2, Experiment I) .
To further distinguish between in vitro and in vivo priming, we compared the CTL precursor frequency to NS3 1406-1415 in unfractionated PBMC and CD45 RO-depleted PBMC from donor C-7 who previously responded to this peptide in bulk culture (Fig. 2, Experiment II) and in a previous LDA (Fig. 6  B) using an approach previously described by Merkenschlager et al. (29) . FACS analysis of unseparated PBMC revealed 29.9% CD45 RO+ cells. Subsequent limiting dilution analysis revealed a sevenfold reduction of peptide-specific CTL precursors after removal of the CD45 RO + memory T cell population (Table VI) indicating that the majority of CTL precursors had been primed in vivo. Similarly, we analyzed the CTL precursor frequency to NS3 1406-1415 in unfractionated PBMC and CD45 RO-depleted PBMC from donor C-3 who previously responded to this peptide in bulk culture ( Fig. 1) and in a previous LDA (Fig. 6 A) and found a fourfold reduction of peptidespecific CTL precursors after removal of the CD45 RO + memory T cell population (Table VI) Effector/Target Cell Ratio Observations made during this study confirm and extend previous reports from this laboratory about the CTL response to HBV encoded epitopes in subjects with acute and chronic HBV infection (6) (7) (8) . In those studies, HBV-specific CTL were readily identified in the peripheral blood of patients with acute hepatitis but were not detectable in patients with chronic hepatitis B or in uninfected normal subjects. In the current study, however, 2 of the 4 chronic HBV patients responded to one or both of the HBV peptides we used (Figure 2 ). This suggests that HBV-specific CTL precursors are indeed present in these patients, albeit at low precursor frequencies ( The reason why we could detect HBV-specific CTL responses in the two patients with chronic hepatitis B in the current study, while we didn't in our previous reports is not immediately evident. These patients were not included in any of our previous reports, so they may simply represent a previously undetected CTL responsive subset of patients with chronic HBV infection. In our previous studies, however, we used recombinant HBcAg as a source of T cell help, while in the current report tetanus toxoid was used. Conceivably, the current responses to the HBV peptides in chronically infected patients, and to the HCV peptides by uninfected controls, may be related to this difference, or it could be due to the longer in vitro stimulation period we employed before the first CTL assay. Obviously, additional studies will be required to clarify this interesting issue.
Two lines of evidence suggest that at least some of the CTL in the peripheral blood of HCV infected patients have been primed in vivo. First, we showed that HCV peptide-specific CTL precursors are present in higher numbers in HCV infected than in uninfected subjects. Second, we showed that, in the two cases tested, they belong to the CD45 RO' "memory" T cell subset. The HCV-specific CTL precursor frequencies we observed in the peripheral blood are in the range of 1/105 to 106 PBMC. Assuming that 80% of PBMC are lymphocytes, 60% of which are T cells, and that 20% the T cells are CD8 +, the CTL precursor frequencies translate to 1/30,000 to 1/300,000 CD8 + T cells. These relatively low frequencies are in part explained by the fact that our experimental system focuses on single epitopes restricted by single restriction elements. Importantly, comparable precursor frequencies were observed for an HLA-A2 restricted epitope in the influenza matrix protein when PBMC from presumably previously infected normal blood donors were studied. Several groups have applied limiting dilution analysis to quantitate HIV-specific CTL precursors in the peripheral blood in infected donors. In one study the gag p24 peptide-specific CTLp frequency was between 120-280/106 PBMC in asymptomatic HIV-I infected hemophiliacs (31). In lymphoid tissue on the other hand, another group reported a frequency of 1/105 to 1/106 CTL specific for a nef peptide 182-206 restricted by HLA-Al and B8 (32) . These differences are in accord with the finding that the cytotoxic response to HIV is particularly vigorous, allowing the detection of effector cells directly from the blood without prior in vitro expansion (33) .
Since we observed the primary in vitro induction of CTL to all four of the HCV CTL epitopes we tested in normal individuals (albeit at much lower precursor frequency), and since additional experiments with HCV core 35-44 and NS3 1073-1081 also revealed the presence of CTL precursors in uninfected subjects (Cerny et al. manuscript in preparation), the pathogenetic significance of the current observations is not immediately evident. Our findings are clearly relevant, however, for vaccine development and for adoptive immunotherapy. Epitopes from conserved regions of the virus that are generated by the intracellular processing of endogenously synthesized antigen are particularly good candidates for vaccine development. This information, combined with the prevalence and degree of conservation of a given epitope (Table II) , can be used in the design of a peptide-based HCV vaccine. Additionally, the in vitro generation of large numbers of biologically active, virus-specific effector cells is a prerequisite for adoptive immunotherapy. The techniques described in this report permit detection and expansion of naive peripheral blood CTL precursors to candidate viral peptides. The use of this simple culture system could make the large scale ex vivo expansion of specific CTL possible.
